Harvard Apparatus Regenerative Technology, Inc. (HRGN) intrinsic value & 10-year financials
Harvard Apparatus Regenerative Technology, Inc. (HRGN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 27.0% a year to $704.0K, with an average return on invested capital of -794.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.23
- Market cap
- $30.0M
- Revenue (FY2025)
- $704.0K
- Revenue growth (10-yr CAGR)
- 27.0%
- ROIC (10-yr avg)
- -794.7%
- Free cash flow (FY2025)
- —
HRGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $704.0K | -$6.9M | — | — | -982.2% | -1905.0% |
| FY2024 | $430.0K | -$7.7M | — | -$4.9M | -1796.7% | -719.0% |
| FY2023 | $103.0K | -$8.9M | -$0.67 | -$7.0M | -8728.2% | 564.4% |
| FY2022 | — | -$6.1M | -$0.55 | -$5.1M | — | 141.3% |
| FY2021 | $0 | -$8.0M | -$0.79 | -$2.6M | — | 395.1% |
| FY2020 | $0 | -$4.9M | -$0.55 | -$4.0M | — | -2216.4% |
| FY2019 | $0 | -$8.3M | — | -$6.2M | — | -1905.5% |
| FY2018 | $0 | -$7.5M | — | -$7.8M | — | -1177.3% |
| FY2017 | $0 | -$11.9M | — | -$11.2M | — | -441.3% |
| FY2016 | $82.0K | -$11.6M | — | -$9.4M | -14787.8% | -683.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Harvard Apparatus Regenerative Technology, Inc. is a consistent compounder, expanding top-line revenue at 27.0% annually over the past decade.
Harvard Apparatus Regenerative Technology, Inc. has historically struggled to out-earn its cost of capital, averaging just 6.0% ROIC.
Harvard Apparatus Regenerative Technology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Harvard Apparatus Regenerative Technology, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-16.96 per share.